18:01 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy Patient sample and mouse studies suggest agonizing FFAR1 could help treat temporal lobe epilepsy. In postmortem brain tissue samples from patients with temporal lobe epilepsy, neocortical levels of FFAR1 protein were higher than...
20:53 , Oct 5, 2017 |  BC Innovations  |  Translation in Brief

AMPK addendum

A...
20:00 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease Mouse studies suggest AMPK activators could help treat non-alcoholic fatty liver disease (NAFLD). In mice, liver-specific expression of an overactive human mutant AMPK decreased glucose production and fatty acid synthesis compared with...
19:00 , Mar 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Myotonic dystrophy type 1 (DM1) Patient sample and mouse studies suggest activating AMPK or inhibiting mTORC1 could help treat DM1. In muscle tissue samples from patients and a genetic mouse model of DM1, levels...
18:15 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes...
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ghrelin; acyl-ghrelin; AMP-activated protein kinase (AMPK)

Neurology INDICATION: Parkinson's disease (PD) Mouse and cell culture studies suggest activating the ghrelin- AMPK pathway could help treat PD. In a mouse model of PD, caloric restriction, which elevates plasma level of ghrelin ,...
08:00 , Feb 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair; osteoporosis Free fatty acid receptor 1 (FFAR1; GPR40) Studies in mice suggest GPR40 agonists could help prevent bone...
08:00 , Jan 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Free fatty acid receptor 1 (FFAR1; GPR40) In vitro and mouse studies identified an alkyne series of FFAR1 agonists that could help treat...
07:00 , Aug 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Free fatty acid receptor 1 (FFAR1; GPR40) Mouse and in vitro studies have identified GPR40 agonists that could help treat type 2 diabetes....
07:00 , Apr 30, 2012 |  BioCentury  |  Product Development

Beyond statins: LDL diversity

No fewer than 20 companies are working on next-generation lipid-lowering agents intended to improve upon the benefits of statins, which lower LDL-C and reduce the risk of cardiovascular events but still leave millions of people...